| Report ID | 283141 |
| Drug Identification Number | 02496364 |
| Brand name | XOFLUZA |
| Common or Proper name | Baloxivir Marboxil |
| Company Name | HOFFMANN-LA ROCHE LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | BALOXAVIR MARBOXIL |
| Strength(s) | 20MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 2 x 20mg Tablets |
| Anatomical Therapeutical Chemical (ATC) code | J05AX |
| Anatomical Therapeutical Chemical (ATC) description | |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | 2026-04-20 |
| Actual start date | 2026-04-20 |
| Estimated end date | Unknown |
| Actual end date | |
| Shortage status | Anticipated shortage |
| Updated date | 2026-04-17 |
| Company comments | Due to changes in the production of Xofluza, the 40mg strength is changing formulations. The 2x20mg tablets (DIN# 02496364) have a direct replacement for patients of the 1x40mg tablets (DIN# 02496372). There will be no patient impact by switching the formulation to 1x40mg tablets (DIN# 02496372). All wholesalers and distributors will be made aware of this change in formulation. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 7070 MISSISSAUGA ROAD MISSISSAUGA, ONTARIO CANADA L5N 5M8 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2026-04-17 | French | Compare |
| v2 | 2026-04-17 | English | Compare |
| v1 | 2026-04-17 | English | Compare |
Showing 1 to 3 of 3